The World ADC Awards showcase companies, teams, and individuals in the industry, across 9 categories, at the forefront of cancer research today. Finalists and winners were shortlisted from over 1,000 votes cast and each submission was evaluated by a panel of seven judges. The awards ceremony virtually took place on September 17, 2020. World ADC is pleased to publish the winners of the 7th Annual World ADC Awards, held at World ADC Digital in September 2020

The World ADC Awards reward the innovation, leadership, and devotion shown by the best companies, teams, and individuals in the industry. Across ten categories the Awards exist to recognize the extraordinary endeavors, teamwork, and commercial acumen that has propelled the field to the forefront of cancer research today.

The Awardees were shortlisted by over 1,000 nominations and then scientific proposals from each were evaluated by our judging panel.

“Every year the judges are impressed with the level of innovation and scientific breakthroughs that these companies are driving. This year is no exception and we are delighted to see the caliber and quantity of entries – showing the growing momentum and advances being made within the industry,” noted Elayda Hearne, Brand Director, World ADC.

Advertisement #3 

“The World ADC Summit is my favorite scientific conference as it unifies all ADC players on to a single platform. In addition, World ADC Awards brings to light the excellence within the ADC field. The World ADC Awards recognizes the innovation, leadership, and devotion on a global platform. I am truly honored to be part of the judging for World ADC Awards and I am delighted to see the growth in the ADC field and the continuing momentum and progress in the ADC field,” Jagath Reddy Junutula, Senior Vice President, R&D at ModMab Therapeutics and a World ADC Judge.

The shortlist for Best ADC platform technology included  as follows:



The 2020 winners are

Best ADC Platform Technology

    • Winner – Synaffix
    • Runner Up – LegoChem Bio

“We are greatly honored to be recognized with the award for Best ADC Platform Technology as voted by our industry peers. Our team has worked passionately to provide cutting-edge ADC-enabling technologies, and we have now built what we believe to be an industry-leading platform to enable best-in-class ADC product candidates. Being recognized with this award serves to validate the significant efforts we have already made towards becoming the most prevalent technology across new clinical-stage ADCs,” said Peter van de Sande, Chief Executive Officer of Synaffix.

Most Promising Clinical Candidate

Best Contract Manufacturing (CMO) Provider

      • Winner – Piramal
      • Runner Up – BSP Pharmaceuticals

Best Contract Research (CRO) Provider

      • Winner – Abzena
      • Runner Up – NJ Biopharmaceuticals

Best New Drug Developer

“This year has certainly been a challenging one, and throughout the pandemic, our team has continued to work around the clock to avoid hurdles and overcome difficulties, while maintaining the progress of our programs and developmental pipeline with the ultimate goal of bringing life-saving solutions to patients. The Best New Drug Developer award received at the World ADC Digital Event highlights the enormous potential of our ADC pipeline, STRO-001, STRO-002, and CC-99712. We are encouraged by our emerging and promising clinical data and the patient benefit that these product candidates may offer,” said William (Bill) J. Newell, Chief Executive Officer and a member of Sutro Biopharma’s Board of Directors.

Best Pre-Clinical Publication 2019


      • Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, Rossi DJ. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat Commun. 2019 Feb 6;10(1):617. doi: 10.1038/s41467-018-08201-x. PMID: 30728354; PMCID: PMC6365495. [Article]
        • In the article, the authors conclude that that CD117-ADC-mediated hematopoietic stem cell transplantation (HSCT) pre-treatment could serve as a non-myeloablative conditioning strategy for the treatment of a wide range of non-malignant and malignant diseases, and might be especially suited to gene therapy and gene editing settings in which preservation of immunity is desired.
      • Yamada K, Shikida N, Shimbo K, Ito Y, Khedri Z, Matsuda Y, Mendelsohn BA. AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies. Angew Chem Int Ed Engl. 2019 Apr 16;58(17):5592-5597. doi: 10.1002/anie.201814215. Epub 2019 Mar 29. PMID: 30854738.[Article]
        • In this article, the authors report a new method of affinity peptide-mediated regiodivergent functionalization (AJICAP™) that enables the synthesis of ADCs from native IgG antibodies.

Best Clinical Publication 2019


      • von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. PMID: 30516102. [Article]
        • In the article, the authors conclude that among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone. The study (KATHERINE number, NCT01772472), was funded by Roche/Genentech.

Individual Input to the Field 2019/2020

Winner: Aldo Braca, President & Founder, BSP Pharmaceuticals

“Very happy and honored to have received this recognition. The BSP Pharmaceuticals team is very active in trying to anticipate customer needs in development, clinical, and commercial supplies. We decided to play an important role as CDMO in the ADC space ten years ago, and we have always been very consistent with this mission, trying to make available to the most qualified scientific community the means to be able to materialize its ideas as quickly as possible.

We are continuing to invest to open up new capacities, both for Drug Substances and Drug Products. We are convinced that this category of treatments is opening new horizons in the fight against cancer and, for many patients, will represent the strongest life expectancy.  BSP is working on most of the new products currently in pre-clinical and clinical and also those that are in the market. We are doing it without too much noise but with a lot of passion. If such an important Community, brought together by Hanson Wade, notices us and appreciates our work, then this shows us that we are going on the right path, it repays us for the work and pushes us to do more and more ”.

Long-Standing Contribution

Rakesh Dixit, Ph.D., DABTWinner: Rakesh Dixit, President & CEO, BioNavigen

“World ADC, organized by Hanson Wade, is the biotech industry’s most comprehensive antibody-drug conjugate conference that enables scientists from all over the world to share the excellence in discovery and development of ADCs. Along with anticancer immunotherapies, ADCs are rapidly becoming one of the fiercest weapons against deadly cancers, and I am thrilled to have a long-standing contribution to the world of ADCs.  It is a great honor and privilege to receive the prestigious “Long-Standing Contributions to the ADC Field” award from the World ADC 2020.  I do not have enough words to express how grateful I am to Hanson Wade, all my peers, and colleagues who nominated me and selected me to receive one of the best honors of my career. Thank you,” Rakesh Dixit said.

For more information about the World ADC Awards, visit

About World ADC & What’s Next
Focused on ADCs and crafted with the field’s thought-leaders, World ADC is the industry’s definitive forum for learning and networking.

Your next opportunity to learn the latest ADC intelligence and foster connections with thought leaders to maximize the therapeutic index of your ADC candidate will be at World ADC Europe.

Join the ADC community for this exclusively digital meeting from March 8th-11th, 2021.

Featured image: World ADC 2019. Photo courtesy: © 2019 – 2020 Hanson Wade. Used with permission.

Advertisement #4